We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From May 2019 to May 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Monday said it filed for U.S. Food and Drug Administration approval of a six-month dose of paliperidone palmitate for the treatment of adults diagnosed with schizophrenia.
The drug maker said the indication, if approved, would make paliperidone palmitate the first and only long-acting injectable schizophrenia treatment with a twice-yearly dosing regimen.
Janssen already markets paliperidone palmitate in a three-month regimen as Invega Trinza and in a monthly dose as Invega Sustenna. Janssen said the new regimen is intended for use only after patients have been stabilized on a shorter acting formulation of paliperidone palmitate, with the goal of administering fewer injections.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 02, 2020 08:49 ET (13:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
